NeoGenomics rises on better-than-expected 2025 revenue forecast
15/01/2025 13:32
** Shares of cancer testing services co NeoGenomics NEO.O
rise ~5% to $14.47 premarket
** NEO forecast FY 2025 revenue in the range of $735 mln to
$745 mln vs analysts' average estimate of $727.70 mln - data
compiled by LSEG
** 10 of 15 brokerages rate stock "buy" or higher and 5
"hold"; their median PT is $19.50 - data compiled by LSEG
** NEO gained 3.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on NeoGenomics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
NeoGenomics rises after BTIG upgrades to 'buy'
Brief: Neogenomics Announces Executive Leadership And Board Of Directors Succession Plan
Brief: Neogenomics Receives Medicare Coverage For Radar St For Immunotherapy Treatment Response Monitoring